Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 10127.123 | 1.0081 | 1.0185 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 10127.123 | 0.8677 | 0.7010 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 10127.123 | 0.8733 | 0.7137 | 0.8767 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9777.124 | 1.0758 | 1.2469 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9777.124 | 1.1484 | 1.4931 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9777.124 | 1.2629 | 1.9007 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9777.124 | 0.9766 | 0.9260 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9777.124 | 0.9637 | 0.8856 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9777.124 | 1.0847 | 1.2765 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9777.124 | 1.1960 | 1.6597 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9777.124 | 1.0315 | 1.1011 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9777.124 | 0.9258 | 0.7689 | 0.6278 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9797.006 | 1.0263 | 1.1277 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9797.006 | 0.8086 | 0.2055 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9797.006 | 1.0217 | 1.1052 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9797.006 | 1.0810 | 1.4078 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9797.006 | 1.1133 | 1.5829 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9797.006 | 1.0618 | 1.3070 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9797.006 | 1.0237 | 1.1147 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9797.006 | 0.8356 | 0.3037 | 0.4196 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9797.006 | 0.8152 | 0.2291 | 0.4196 | |
| SUM149PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7917.018 | 1.0107 | 1.0075 | 2.8573 | |
| SUM149PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7917.018 | 0.9639 | 0.9744 | 2.8573 | |
| SUM149PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7917.018 | 0.9622 | 0.9732 | 2.8573 | |
| SUM149PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7917.018 | 1.0159 | 1.0111 | 2.8573 |